Re-Treatment With Immune Checkpoint Inhibitors

Details

Files

Project Status:

Completed

Project Line:

Health Technology Review

Project Sub Line:

Summary with Critical Appraisal

Project Number:

RC1544-000

Key Message

We did not find any evidence regarding the clinical effectiveness and safety of second re-treatment with pembrolizumab for nonsmall cell lung cancer, classical Hodgkin lymphoma, and advanced melanoma.

We did not find any evidence regarding the clinical effectiveness and safety of second re-treatment with cemiplimab for cutaneous squamous cell carcinoma.

We did not find any evidence-based guidelines regarding the second re-treatment with immune checkpoint inhibitors for nonsmall cell lung cancer, classical Hodgkin lymphoma, advanced melanoma, and cutaneous squamous cell carcinoma.

Files

Final Report View PDF

Last Updated : August 6, 2024